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Abstract: Sebaceous gland hyperplasia (SGH) is a benign condition that originates in the sebaceous follicles and 
occurs most commonly on the forehead and cheek. It is very rarely found in the genital region; however, a few 
case reports have described SGH of the vulva. We recently encountered a case of vulvar SGH in a young woman 
who presented with an asymmetric labium minus and unilateral vulvar hypertrophy. A meticulous histopathological 
and immunohistochemical examination was performed, and the respective literature was reviewed. The clinico-
pathological features and immunophenotype of seven previous cases of vulvar SGH were summarized. A careful 
histopathological examination is required to diagnose vulvar SGH and distinguish it from other vulvar lesions. Given 
that the increasing incidence of vulvar cancer, it is necessary to biopsy any unusual-appearing lesions on the vulva. 
Furthermore, it is important to perform histopathological examinations of these lesions to rule out intraepithelial 
neoplasia or malignancy.
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Introduction
Sebaceous gland hyperplasia (SGH) is a benign, 
hamartomatous condition that originates in 
sebaceous follicles. Usually, SGH is usually 
found in older individuals, and is less common 
among younger people [1, 2]. It presents as 
solitary or multiple, yellow, umbilicated papules 
or nodules that most commonly occur on the 
forehead and cheek. Occasionally, SGH affects 
the areola, chest, or genital skin [3, 4].
Excluding the palms and soles, sebaceous 
glands are ubiquitous in the skin. They are usu-
ally found in association with hair structures; 
however, free sebaceous glands (that are not 
associated with hair) also occur in areas of 
modified skin, such as the nipple and areola in 
men and women. Free sebaceous glands are 
also found on the labium minus and the inner 
aspect of the prepuce [5]. The labium minus 
does not usually contain skin appendages. 
However, in some individuals, the lateral labium 
minus has sebaceous and sweat glands. The 
sebaceous gland elements are medial and pos-
terior to the labium minus at the junction with 
the vulvar vestibule [6].
SGH on the vulva is quite rare, and only a few 
cases have been reported in the literature [2, 
5-10]. Therefore, it is important for clinicians to 
be aware of this entity and recognize that its 
clinical presentations on the vulva are variable. 
The differential diagnosis of vulvar SGH includes 
a variety of inflammatory and neoplastic lesions 
of the vulvoperineal skin. Pathologists should 
consider SGH examining an unusual vulvar 
lesion.
Patient and methods
Case presentation
An 18-year-old nulligravid woman presented 
with an asymmetric vulva. One year prior to pre-
sentation, the patient noticed vaginal discharge 
and enlargement of the right labium minus. 
Menarche occurred at 12 years of age, and the 
patient’s menstrual cycles were regular. Her 
gynecological history was unremarkable. She 
was not taking oral contraceptives. On exami-
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nation, there was a soft lesion in the right vulva 
measuring 1.2×1.0×1.0 cm. The lesion was 
covered with normal-appearing skin without 
apparent texture changes. The surrounding 
skin was also unremarkable. A local excision 
with labioplasty was performed.
Histopathological examination
The resected material was fixed in neutral-buff-
ered formalin and was embedded in one paraf-
fin block. Four-micrometer sections were cut 
from the block and stained with hematoxylin 
and eosin. The sections were prepared for 
immunohistochemical staining. Slides were 
examined under routine light microscopy.
Immunohistochemistry
The tissue sections were deparaffinized and 
rehydrated with xylene and alcohol solution. 
Immunohistochemical staining was performed 
using the Ventana Discovery XT automated 
staining system (Ventana Medical Systems, 
Inc., Tucson, AZ, USA) according to the manu-
facturer’s instructions. The Cell Conditioning 1 
buffer (citrate buffer, pH 6.0, Ventana Medical 
Systems, Inc.) was used for antigen retrieval. 
The tissue sections were then incubated with 
primary antibodies (Table 1). The ultraView 
Universal DAB Detection Kit (Ventana Medical 
Systems, Inc.) was used to perform the chro-
mogenic visualization step. The slides were 
then counterstained with hematoxylin and 
coverslipped.
Literature review
The Medline database was thoroughly searched 
using the PubMed retrieval service. Searches 
were performed using the key words “seba-
ceous hyperplasia”, “sebaceous”, and “vulva”. 
Seven cases of vulvar SGH were found. The 
clinical and pathological features of the seven 
cases, in addition to our case, were thoroughly 
reviewed.
Results
On gross examination, the resected specimen 
consisted of multiple pieces of the skin, which 
were irregular in size and shape. The largest 
piece measured 1.5×1.0 cm. The skin did not 
have any prominent lesions. However, it was 
slightly thickened with a relatively regular sur-
face. The cut surfaces were pink. Microscopic 
examination revealed a tumor arising from the 
sebaceous glands, which consisted of numer-
ous lobules and extended into the dermis in a 
pattern of well-defined islands (Figure 1B). 
There were significantly more lobules in the 
tumor tissue compared to in the adjacent nor-
mal glands (Figure 1A). The sebaceous gland 
lobules were fully mature; they did not exhibit 
nuclear enlargement, pleomorphism, hyper-
chromasia, or mitotic figures (Figure 1C). The 
cells were predominantly mature sebocytes 
with a peripheral germinal layer, which was not 
prominent. They displayed a foamy, vesiculated 
cytoplasm and centrally located nuclei. The 
lesion also had patchy infiltrate of chronic 
inflammatory cells. 
Both epithelial membrane antigen (EMA; Figure 
1D) and cytokeratin (CK) 5/6 (Figure 1E) immu-
nostaining highlighted scattered hyperplastic 
lobules. In particular, the sebocytes in the cen-
tral portion of the glands were positive for EMA 
(Figure 1F). In contrast, CK 5/6 (Figure 1G), 
p63 (Figure 1H), and the androgen receptor 
reacted in the peripheral germinal layer. The 
specimen was negative for carcinoembryonic 
Table 1. Antibodies used for immunohistochemical staining
Antibody Source Clone Dilution
AR Dako, Agilent Technologies, Inc., Carpinteria, CA, USA AR 441 1:100
CEA Dako, Agilent Technologies, Inc., Carpinteria, CA, USA II-7 1:400
CK 5/6 Dako, Agilent Technologies, Inc., Carpinteria, CA, USA D5/16 B4 1:200
EMA Dako, Agilent Technologies, Inc., Carpinteria, CA, USA E29 1:200
ER Thermo Fisher Scientific, Inc., Fremont, CA, USA SP1 1:100
PR Dako, Agilent Technologies, Inc., Carpinteria, CA, USA PgR 636 1:50
p63 Dako, Agilent Technologies, Inc., Carpinteria, CA, USA DAK-p63 1:150
SMA Dako, Agilent Technologies, Inc., Carpinteria, CA, USA 1A4 1:500
AR: androgen receptor; CEA: carcinoembryonic antigen; CK: cytokeratin; EMA: epithelial membrane antigen; ER: estrogen 
receptor; PR: progesterone receptor; SMA: smooth muscle actin.
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antigen, estrogen receptor, progesterone re- 
ceptor, and smooth muscle actin.
Discussion
Vulvar SGH is very rare, with only seven report-
ed cases in the literature. Tables 2 and 3 list 
the clinical and pathological features of these 
seven cases, in addition to the case presented 
here. The patient age ranged between 18 and 
50 years (mean 32.5 years). In five of the eight 
patients, vulvar SGH presented as a single, uni-
lateral lesion in the labium minus or labium 
majus. In the three other patients, SGH pre-
sented with multiple lesions that were not only 
in the labium minus or majus, but also in the 
mons veneris or vestibule. Five of the eight 
patients presented with polypoid lesions, which 
have been previously described as vulvar SGH-
specific manifestations [2, 5, 7, 8]. However, 
the three other patients presented with irregu-
lar cutaneous lesions or mucosal thickening or 
a sessile nodule. Therefore, it is difficult to con-
clude that a polypoid appearance is a classic 
indicator of vulvar SGH. Interestingly, two 
patients also had hyperpigmented lesions. 
With regard to the variable clinical findings 
described, SGH should be considered in the 
case of a polypoid, sessile or pigmented lesion 
on the vulva. Our literature review demon-
strates that vulvar SGH presents with various 
signs and symptoms. Although the lesion 
Figure 1. Histopathological and immunohistochemical findings of vulvar sebaceous gland hyperplasia. (A) Normal 
epidermis and sebaceous glands of the labium minus. The sebaceous glands are embedded in the dermis. Each 
gland consists of several lobules. (B) Low-power view of vulvar SGH. The lesion contains an increased number of 
sebaceous glands with multiple, enlarged, irregularly-arranged lobules. (C) High-power view of Image (B). Each lob-
ule consists of numerous, fully mature sebaceous cells (sebocytes) containing sebum. There are no cytologic atypia 
or mitotic figures. (D and E) Low-power view of (D) EMA and (E) CK 5/6 immunostaining. The lobules demonstrate 
diffuse and strong immunoreactivity to both markers. (F) High-power view of Image (D). The sebocytes in the central 
portion of the gland are strongly positive for EMA. (G) High-power view of Image (E). The peripheral germinative layer 
exhibits strong positivity for CK 5/6. (H) High-power view of p63 immunostaining. Similar to CK 5/6, p63 reacts with 
cells in the peripheral germinative layer.
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Table 2. Clinical features of eight published cases of vulvar sebaceous gland hyperplasia
Case Author Age Location Clinical presentation Clinical diagnosis Associated condition
1 Rocamora et al. [2], 1986 32 Right labium majus (two) and 
mons veneris (one)
Three soft, nontender, umblicated lesions Condyloma acuminatum, soft fibroma None
2 Ortiz-Rey et al. [5], 2002 19 Left labium majus A soft, polypoid mass covered by normal appearing skin Not available None
3 Bakaris et al. [6], 2004 37 Both labia minora Regularly shaped, smooth, tender tumors
covered by normal appearing skin
Not available Vulvar discomfort, dyspareunia
4 Malliah et al. [8], 2006 50 Left labium minus Severe burning sensation of vulva Not available Remote Bartholin cyst
5 Masmoudi et al. [9], 2006 27 Left labium majus Multiple soft, nontender lesions Not available None
6 Al-Daraji et al. [7], 2007 31 Left labium minus, vestibule Two soft, nontender, pigmented lesions covered by 
normal appearing skin
Melanocytic macule, benign tumor None
7 Mora et al. [10], 2010 45 Left labium minus Irregular thickening and recurrent inflammatory changes 
of the skin
Hidradenitis suppurativa Lymphedema, recurrent dermati-
tis, recurrent epidermoid cyst
8 Present case, 2016 18 Right labium minus A single, skin-colored, soft, nontender mass causing 
asymmetric labia minora
Unilateral labial hypertrophy Vaginal discharge
Table 3. Pathological features of eight published cases of vulvar sebaceous gland hyperplasia
Case Author Size (mm) Gross appearance Histopathological diagnosis Immunostaining result
1 Rocamora et al. [2], 1986 15 Polypoid lesions Sebaceous gland hyperplasia Not available
2 Ortiz-Rey et al. [5], 2002 25 A polypoid tumor Sebaceous gland hyperplasia AR (P), EMA (P), ER (N), PR (N)
3 Bakaris et al. [6], 2004 25 Polypoid, multilobed masses Sebaceous gland hyperplasia EMA (P)
4 Malliah et al. [8], 2006 50 Slight mucosal thickening, hyperpigmentation Sebaceous gland hyperplasia Not available
5 Masmoudi et al. [9], 2006 5 Multiple polypoid lesions Sebaceous gland hyperplasia Not available
6 Al-Daraji et al. [7], 2007 12 Pigmented, polypoid lesions Sebaceous gland hyperplasia EMA (P)
7 Mora et al. [10], 2010 20 Irregular skin thickening Sebaceous gland hyperplasia CK 5/6 (P), EMA (P), p63 (P), SMA (N), CEA (N), CgA (N)
8 Present case, 2016 12 A sessile nodule Sebaceous gland hyperplasia CK 5/6 (P), EMA (P), p63 (P), AR (P), SMA (N), CEA (N), ER (N), PR (N)
AR: androgen receptor; EMA: epithelial membrane antigen; ER: estrogen receptor; PR: progesterone receptor; CK 5/6: cytokeratin 5/6; CEA: carcinoembryonic antigen; CgA: chromogranin A; SMA: smooth muscle actin.
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described in this report was soft, nontender 
and covered with normal-appearing skin, other 
cases have described a burning sensation, dys-
pareunia, or vaginal discharge. Still further, vul-
var SGH may present with recurrent dermatitis 
caused by eczematous, inflammatory change. 
Our patient complained of vulvar asymmetry 
caused by unilateral labial hypertrophy. A ses-
sile nodule (and not necessarily a distinct 
mass) of vulvar SGH may trigger labial hypertro-
phy. Vulvar SGH was not suspected preopera-
tively in any of the reported cases. This sug-
gests that clinicians are not aware of the clini-
cal findings of vulvar SGH, especially given its 
rarity. Despite having histologically distinctive 
features, vulvar SGH may be misdiagnosed as 
a benign tumor (such as soft fibroma), or as an 
infectious or inflammatory lesion (such as con-
dyloma acuminatum and hidradenitis suppura-
tiva), or a melanocytic macule. Vulvar SGH has 
several characteristics that distinguish it from 
SGH occurring elsewhere on the body. The 
mean age at which facial SGH occurs is 61.2 
years [7, 11]. In contrast, vulvar SGH occurs at 
a mean age of 32.5 years. In particular, six of 
the eight patients with vulvar SGH were being 
younger than 40 years. Histopathologically, the 
mean size of vulvar SGH was 20.5 mm, which is 
remarkably larger than the usual size of non-
vulvar SGH (2-3 mm). 
To the best of our knowledge, there are no prior 
studies that address the immunophenotype of 
vulvar SGH. However, it is suspected that vulvar 
SGH has a similar immunophenotype to that 
occurring elsewhere on the body. EMA is strong-
ly positive in the sebum-rich sebocytes at the 
central portion of the sebaceous gland lobule. 
In the peripheral germinative layer, CK 5/6, 
p63, and AR are positive. These findings are 
specific to SGH, and can be useful in its diagno-
sis. Clinically, the differential diagnosis of vul-
var SGH includes fibroepithelial polyps (if po- 
lypoid), condylomata acuminata, inflammatory 
processes such as comedos and furuncles, 
and cutaneous neoplasms. Histopathologically, 
the differential diagnosis includes other vulvo-
perineal lesions consisting mostly of mature 
sebaceous glands such as nevus sebaceous of 
Jadassohn, sebaceous gland carcinoma, follic-
ulosebaceous cystic hamartoma, sebaceous 
trichofolliculoma, and sebaceoma [2].
Although the exact pathogenesis of SGH is not 
yet known, several environmental factors are 
suspected to play a role. Ultraviolet radiation, 
for example, may represent a cofactor involved 
in its development [12]. Prolonged ultraviolet 
radiation exposure has been reported to cause 
SGH in hairless mice [13]. However, this result 
may not be applicable to vulvar SGH, as there is 
usually limited ultraviolet exposure to the peri-
neal area. Nodules of mucus-secreting glands 
have also been associated with prior surgery or 
states of chronic inflammation [14]. In addition, 
SGH has been reported in 16% of immunocom-
promised organ transplant recipients [15]. 
None of the above-mentioned factors was iden-
tified in our patient.
Potential treatments for SGH include cryothera-
py, cauterization, topical chemicals, and surgi-
cal excision. It is noteworthy that none of the 
eight reported cases (including the present 
case) recurred after treatment. Future large 
cohort studies are needed to clarify the clinical 
outcome of and therapeutic options for SGH. 
Diagnosing vulvar SGH and distinguishing from 
another vulvar lesion requires a thorough 
examination of the lesion and an identification 
of this rare entity. The incidence of vulvar carci-
noma is increasing, which makes it necessary 
to biopsy any unusual-appearing lesions on the 
vulva. It is similarly important to perform metic-
ulous histopathological examinations of vulvar 
lesions to exclude intraepithelial neoplasia or 
malignancy.
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